NGL Fine Chem Ltd

NGL Fine Chem Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

NGL Fine Chem Ltd

₹ 1,327 0.56%
12 Dec - close price
nglfinechem.com BSE: 524774 NSE: NGLFINE
About

Incorporated in 1981, NGL Fine-Chem Ltd is a manufacturer and exporter of pharmaceuticals and intermediates for usage in veterinary and human health.[1]

Key Points

Business Overview:[1][2]
NGLFCL primarily manufactures veterinary pharmaceutical APIs and intermediates, catering to the antiprotozoal and anthelmintic therapeutic segments. Its products are used in the animal healthcare industry.

Product Profile:[3][4]
It has ~39 APIs (37 Veterinary APIs, 2 Human APIs), ~4 Intermediates, and ~12 finished dosage forms, etc., in the categories of Anthelmintics, Antiprotozoals, Ectoparasiticides, and Phosphorus Supplements

Website BSE NSE
  • Market Cap ₹ 820 Cr.
  • Current Price ₹ 1,327
  • High / Low ₹ 2,161 / 957
  • Stock P/E 39.6
  • Book Value ₹ 486
  • Dividend Yield 0.13 %
  • ROCE 9.44 %
  • ROE 7.75 %
  • Face Value ₹ 5.00
Edit ratios

Pros

  • Company's working capital requirements have reduced from 64.9 days to 50.4 days

Cons

  • Stock is trading at 2.73 times its book value
  • Company has a low return on equity of 11.4% over last 3 years.
  • Dividend payout has been low at 4.34% of profits over last 3 years

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025
67.72 71.93 75.13 71.04 80.18 87.95 99.76 90.75 93.48 89.10 94.97 104.19 120.26
58.57 62.12 60.93 61.18 66.21 74.08 83.94 81.40 81.92 84.01 88.65 93.21 103.10
Operating Profit 9.15 9.81 14.20 9.86 13.97 13.87 15.82 9.35 11.56 5.09 6.32 10.98 17.16
OPM % 13.51% 13.64% 18.90% 13.88% 17.42% 15.77% 15.86% 10.30% 12.37% 5.71% 6.65% 10.54% 14.27%
0.47 0.69 0.87 3.32 3.22 3.68 3.68 5.88 5.12 -0.13 -0.97 6.35 2.05
Interest 0.12 0.26 0.34 0.24 0.36 0.28 0.49 0.44 0.32 0.60 0.97 1.22 1.16
Depreciation 3.25 1.23 2.68 2.86 2.89 2.94 2.92 3.00 3.03 3.10 3.32 4.27 5.09
Profit before tax 6.25 9.01 12.05 10.08 13.94 14.33 16.09 11.79 13.33 1.26 1.06 11.84 12.96
Tax % 25.44% 28.08% 22.66% 15.58% 24.82% 30.01% 23.43% 21.80% 26.41% -0.79% 49.06% 21.96% 25.77%
4.67 6.49 9.32 8.51 10.48 10.03 12.32 9.22 9.81 1.28 0.54 9.24 9.63
EPS in Rs 7.56 10.51 15.09 13.77 16.96 16.24 19.94 14.92 15.88 2.07 0.87 14.96 15.59
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 TTM
153 152 258 318 278 339 368 409
121 130 178 249 243 285 333 369
Operating Profit 32 22 80 68 35 54 35 40
OPM % 21% 14% 31% 21% 13% 16% 9% 10%
4 1 8 11 6 14 9 7
Interest 3 3 2 2 2 2 3 4
Depreciation 6 8 8 10 11 12 12 16
Profit before tax 28 12 78 67 27 54 28 27
Tax % 27% 31% 27% 25% 25% 24% 24%
20 8 57 50 20 41 21 21
EPS in Rs 32.58 13.50 91.81 80.77 33.18 66.88 34.19 33.49
Dividend Payout % 5% 13% 2% 2% 5% 3% 5%
Compounded Sales Growth
10 Years: %
5 Years: 19%
3 Years: 5%
TTM: 10%
Compounded Profit Growth
10 Years: %
5 Years: 17%
3 Years: -25%
TTM: -50%
Stock Price CAGR
10 Years: 15%
5 Years: 4%
3 Years: -7%
1 Year: -30%
Return on Equity
10 Years: %
5 Years: 18%
3 Years: 11%
Last Year: 8%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Sep 2025
Equity Capital 3 3 3 3 3 3 3 3
Reserves 89 96 151 200 219 260 279 297
27 28 16 30 32 34 77 88
23 26 36 44 32 59 74 96
Total Liabilities 142 154 207 277 287 356 433 484
61 68 64 89 88 86 143 170
CWIP 0 0 12 6 26 46 50 35
Investments 9 11 29 29 39 54 60 49
73 75 102 153 133 171 181 230
Total Assets 142 154 207 277 287 356 433 484

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
9 20 27 14 35 20 36
-10 -20 -25 -14 -27 -27 -35
0 -1 -1 -1 -1 -1 -1
Net Cash Flow -1 -0 2 -1 7 -7 0

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 79 63 53 74 86 97 81
Inventory Days 106 155 132 137 69 98 101
Days Payable 92 116 103 91 63 112 113
Cash Conversion Cycle 93 102 82 120 93 83 68
Working Capital Days 70 58 69 90 68 76 50
ROCE % 14% 54% 34% 12% 20% 9%

Shareholding Pattern

Numbers in percentages

Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025
73.81% 73.53% 73.53% 73.06% 73.06% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74% 72.74%
0.00% 0.00% 0.00% 0.02% 0.04% 0.10% 0.03% 0.02% 0.05% 0.00% 0.00% 0.00%
0.00% 0.00% 0.01% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
26.19% 26.47% 26.46% 26.93% 26.91% 27.16% 27.24% 27.25% 27.23% 27.26% 27.26% 27.26%
No. of Shareholders 18,44018,28717,06617,62316,41015,04114,60814,57514,11014,38614,01013,387

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls